Authors: Ji W et al.
Anesthesia & Analgesia, 2026.
Beyond the Binary: Integrating Novel G Protein–Biased Opioids Into the Opioid-Free Anesthesia Debate.
This letter to the editor addresses the ongoing debate surrounding opioid-free anesthesia (OFA) and opioid-based anesthesia (OBA), proposing that the discussion should move beyond a simple binary framework. The authors argue that emerging pharmacologic developments—particularly G protein–biased opioid agonists—may offer an alternative that balances effective analgesia with improved safety.
The authors respond to a previously published discussion on OFA strategies and emphasize that the primary objective of perioperative analgesic strategies should remain reliable and effective pain control. While opioid reduction has become an important goal in modern perioperative care, they caution that complete opioid elimination may compromise analgesia in some patients.
Traditional opioids such as fentanyl, morphine, hydromorphone, and remifentanil activate μ-opioid receptors through two major intracellular signaling pathways: the G protein pathway and the β-arrestin pathway. Activation of the G protein pathway primarily mediates analgesic effects, while β-arrestin signaling is associated with many opioid-related adverse effects, including respiratory depression, nausea, vomiting, gastrointestinal dysfunction, and sedation.
Newer pharmacologic agents known as G protein–biased μ-opioid receptor agonists selectively activate the G protein pathway while minimizing recruitment of the β-arrestin pathway. One example discussed is oliceridine, which has been developed to provide effective analgesia with fewer opioid-related side effects.
Clinical data cited in the letter suggest that oliceridine provides analgesic efficacy comparable to morphine while demonstrating an improved safety profile. In particular, studies have shown reductions in respiratory depression of approximately 30–50%, along with lower rates of postoperative nausea and vomiting.
The authors suggest that these pharmacologic advances represent a meaningful scientific response to the concerns that have driven interest in opioid-free anesthesia. Rather than abandoning opioids entirely, incorporating G protein–biased opioid agonists into perioperative analgesic strategies could preserve analgesic effectiveness while reducing complications.
The authors propose that these agents may be particularly useful in patients who are poor candidates for traditional OFA strategies. For example, individuals with cardiovascular instability may tolerate opioid-based regimens better than certain non-opioid adjuncts used in OFA protocols.
Ultimately, the authors argue that perioperative anesthesia strategies should move toward a more nuanced and individualized model of analgesic management. Instead of framing the discussion as opioid versus opioid-free anesthesia, clinicians should consider integrating emerging opioid pharmacology into multimodal analgesic strategies.
They call for future research directly comparing G protein–biased opioids with both conventional opioids and opioid-free anesthesia regimens. Such head-to-head studies would help determine whether these newer agents can deliver effective analgesia while improving patient safety and clinical outcomes.
Key Points
• The debate between opioid-free anesthesia and opioid-based anesthesia may be overly simplistic.
• Traditional opioids activate both G protein and β-arrestin signaling pathways.
• Many opioid adverse effects are linked to β-arrestin pathway activation.
• G protein–biased opioids preferentially activate analgesic pathways while reducing β-arrestin signaling.
• Oliceridine has demonstrated analgesia comparable to morphine with fewer respiratory and gastrointestinal side effects.
• These agents may provide a middle ground between conventional opioid use and opioid-free anesthesia strategies.
Thank you to Anesthesia & Analgesia for allowing us to summarize and share this article.